Health Canada approves IBS claims for Lallemand probiotic B. LAFTI B94
The claims approved for the strain Bifidobacterium animalis ssp. Lactis LAFTI B94 by the Natural and Non-prescription Health Products Directorate (NNHPD), the regulatory agency for natural health products in Canada, include:
- “Helps to relieve abdominal discomfort, such as bloating and constipation” at a daily dose of 5 billion CFU
- “Helps children and adolescents with bloating and constipation in irritable bowel syndrome (IBS)”at a daily dose of 10 billion CFU
The first claim was also approved for adults at the same daily dose.
The strain is authorized in infants from 2 months old at a daily dose of 5 billion CFU, with specific probiotic claims such “Participates in a healthy microflora balance.”
Additionally, in adults, the probiotic is also recognized for its benefits as an adjunct to physician-supervised therapy in patients with Helicobacter pylori infections at higher daily doses.
Solange Henoud, Regulatory Affairs Director for Lallemand Health Solutions, commented: “Such specific claims are the achievement of a great teamwork. We are confident they will open the doors to new marketing opportunities for this strain in gut health applications, not only in Canada but also in other territories and competitive markets in support of our customers’ expanding strategies.”
